Celonic AG has pursued an ambitious expansion strategy in mammalian cell line contract manufacturing to establish Phase III and commercial supply by mid-2019. A new GMP facility in Heidelberg was acquired, and capacity is also being expanded at the headquarters in Basel. European Biotechnology spoke with Franzpeter Bracht, COO of Celonic, about Celonic’s strategy.
Roche pays US$2.4bn for FMI take-over
Latest NewsThree years ago Roche acquired a majority in shares of Foundation Medicines Inc (FMI), a specialist in cancer panel sequencing, which has build a huge database with cancer mutation profiles. Now Roche paid US2.4bn to complete the take-over.
Deinobiotics reports novel antibiotics class
Latest NewsResearchers at French antibiotics specialist Deinobiotics SAS, a subsidiary of Deinove SA, and German researchers announces the discovery of a new class of resistance breaking antibiotics that kill MRSA or S. pneumoniae effectively.
EPO under pressure not to lower quality standards
Latest NewsFollowing a letter of about 1,000 EPO patent examiners , also patent attorneys have send an open letter to the European Patent Office (EPO), criticising its outgoing president for having established work routines that are set to lower quality of European patents.
Adrenomed reveals MOA of sepsis antibody
Latest NewsAdrenomed AG announced the publication of three scientific papers revealing how its adrenomedullin-targeting Phase II sepsis antibody Adrecizumab reverses vascular hyperpermeability in sepsis.
Dirk Kersten joins Forbion as General Partner
AppointmentsForbion, a European life science venture capital firm, today announces that Dirk Kersten will join as a General Partner on October 1st, 2018.
Cell Medica Appoints Julia P. Gregory
AppointmentsCell Medica, today announced the appointment of Julia P. Gregory as a Non-Executive Director and Audit Chair of the Company’s Board of Directors.
Angiogenesis, Cell Migration & Invasion Assays
ProductsAngiogenesis, the growth of new blood vessels from pre-existing vasculature, is a normal process in growth and development, as well as in wound healing and tissue granulation.
AMR: FDA provides financing model for novel antibiotics
Latest NewsAs first regulatory body in the world, the FDA has presented a market-driven reimbursement mechanism for antibiotics that may incentivise drug development in a niche market with currently low return on investment.
Tigenix announces change in Board of Directors
AppointmentsTigenix NV, a biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic stem cells, today announces that Eduardo Bravo will depart the board of directors and his role as CEO of Tigenix effective as of June 15, 2018.
Expanding into the commercial supply space
BackgroundCelonic AG has pursued an ambitious expansion strategy in mammalian cell line contract manufacturing to establish Phase III and commercial supply by mid-2019. A new GMP facility in Heidelberg was acquired, and capacity is also being expanded at the headquarters in Basel. European Biotechnology spoke with Franzpeter Bracht, COO of Celonic, about Celonic’s strategy.